Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 5/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104650 | 0.92 | MAPK1 (0.38) | HCAR3JAK2IRAK4CHEK1OPRK1 | |
| SCHEMBL15635529 | 0.87 | JAK2 (0.46) | HCAR3JAK2CHEK1OPRK1 | |
| SCHEMBL871750 | 0.87 | JAK2 (0.46) | HCAR3JAK2CHEK1CSNK2A1OPRK1 | |
| SCHEMBL4110540 | 0.84 | MCHR1 (0.40) | IRAK4ALDH1A1 | |
| SCHEMBL4110544 | 0.84 | MCHR1 (0.40) | IRAK4ALDH1A1 | |
| SCHEMBL12941959 | 0.84 | HCAR3 (0.38) | HCAR3CHEK1CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL4098946 | 0.84 | HCAR3 (0.38) | HCAR3CHEK1CSNK2A1OPRK1CSNK2A2 | |
| SCHEMBL17110968 | 0.83 | MAPK8 (0.43) | HCAR3JAK2IRAK4 | |
| SCHEMBL870326 | 0.82 | SSTR4 (0.46) | JAK2CHEK1CSNK2A1OPRK1CSNK2A2 | |
| SCHEMBL8178773 | 0.81 | MCHR1 (0.40) | JAK2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233907-A1 | Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233907-A1 | Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233907-A1 | Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-1999130-A1 | PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | AstraZeneca AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| US-20080207650-A1 | Chemical Compounds 636 | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207650-A1 | Chemical Compounds 636 | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207650-A1 | Chemical Compounds 636 | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| WO-2008084240-A1 | CHEMICAL COMPOUNDS 636 : PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084240-A1 | CHEMICAL COMPOUNDS 636 : PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084236-A1 | CHEMICAL COMPOUNDS 635 : PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084236-A1 | CHEMICAL COMPOUNDS 635 : PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2007108750-A1 | PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007108750-A1 | PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233907-A1 | Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors | PDE4A, PDE4B, PDE12 | HCAR3 2700/4885JAK2 1996/4885IRAK4 167/4885 |
| US-20080207650-A1 | Chemical Compounds 636 | PDE4A, PDE3B, PDE3A | HCAR3 892/4885JAK2 1305/4885IRAK4 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.